These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21607923)

  • 1. Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.
    Solassol J; Du-Thanh A; Maudelonde T; Guillot B
    Int J Biol Markers; 2011; 26(2):82-7. PubMed ID: 21607923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating prognosis markers in melanoma: proteomic profiling and clinical studies].
    Solassol J; Guillot B; Maudelonde T
    Ann Biol Clin (Paris); 2011; 69(2):151-7. PubMed ID: 21464007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
    Greco M; Mitri MD; Chiriacò F; Leo G; Brienza E; Maffia M
    Cancer Lett; 2009 Oct; 283(2):222-9. PubMed ID: 19394758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
    Bougnoux AC; Solassol J
    Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current staging and prognostic factors in melanoma.
    Bartlett EK; Karakousis GC
    Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
    Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
    Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic strategies for the characterization and the early detection of lung cancer.
    Massion PP; Caprioli RM
    J Thorac Oncol; 2006 Nov; 1(9):1027-39. PubMed ID: 17409991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly sensitive detection of melanoma based on serum proteomic profiling.
    Caron J; Mangé A; Guillot B; Solassol J
    J Cancer Res Clin Oncol; 2009 Sep; 135(9):1257-64. PubMed ID: 19288131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
    Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
    J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.
    Utikal J; Schadendorf D; Ugurel S
    Arch Dermatol Res; 2007 Mar; 298(10):469-77. PubMed ID: 17221215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
    Mian S; Ugurel S; Parkinson E; Schlenzka I; Dryden I; Lancashire L; Ball G; Creaser C; Rees R; Schadendorf D
    J Clin Oncol; 2005 Aug; 23(22):5088-93. PubMed ID: 16051955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
    Lakomý R'; Greplová K; Pilný R; Budinská E; Valík D; Poprach A; Nemecek R; Vyzula R
    Klin Onkol; 2009; 22(5):228-32. PubMed ID: 19886361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
    Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
    J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum angiogenin levels predict treatment response in patients with stage IV melanoma.
    Vihinen P; Kallioinen M; Vuoristo MS; Ivaska J; Syrjänen KJ; Hahka-Kemppinen M; Kellokumpu-Lehtinen PL; Pyrhönen SO
    Clin Exp Metastasis; 2007; 24(7):567-74. PubMed ID: 17762972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serological diagnosis of tumors: methods of marker's search].
    Bukurova IuA; Krasnov GS; Nikitina IG; Karpov VL; Lisitsyn NA; Beresten' SF
    Mol Biol (Mosk); 2013; 47(1):3-11. PubMed ID: 23705492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
    Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
    Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.